Australia's Neurotech International rises on US FDA nod for neurological disorders drug
14/07/2026 02:29
BUZZ-Australia's Neurotech International rises on US FDA nod for neurological disorders drug ** Shares of Neurotech International NTI.AX rise 12.5% to A$0.018, their highest level since December 12
** Biopharma co says U.S. FDA cleared the investigational new drug submission for its NTI164, a drug for improving symptoms of paediatric neurological disorders.
** Shares on track for best day since July 2 if gains hold
** About 11.6 mln shares change hands, 5.5x the 30-day average of 2.1 mln
** Stock up 28.6% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt